S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
Critical asset just had biggest fall on record (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
NASDAQ:SLNO

Soleno Therapeutics (SLNO) Stock Price, News & Analysis

$47.25
-1.94 (-3.94%)
(As of 03/4/2024 ET)
Today's Range
$45.70
$49.81
50-Day Range
$36.04
$52.35
52-Week Range
$1.94
$53.82
Volume
317,035 shs
Average Volume
245,894 shs
Market Capitalization
$1.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.60

Soleno Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
17.7% Upside
$55.60 Price Target
Short Interest
Bearish
8.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
1.20mentions of Soleno Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$5.33 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.55) to ($1.21) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.95 out of 5 stars

Medical Sector

211th out of 960 stocks

Electromedical Equipment Industry

3rd out of 21 stocks


SLNO stock logo

About Soleno Therapeutics Stock (NASDAQ:SLNO)

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

SLNO Stock Price History

SLNO Stock News Headlines

Soleno Therapeutics Inc.
SLNO Apr 2024 65.000 call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
SLNO Mar 2024 40.000 call
SLNO Mar 2024 22.500 put
SLNO Mar 2024 60.000 call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
SLNO Mar 2024 45.000 put
Soleno Therapeutics Inc (SLNO)
Cantor Fitzgerald Keeps Their Buy Rating on Soleno Therapeutics (SLNO)
3 Biotech Stocks With Big-Time Breakthrough Potential
See More Headlines
Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/04/2024
Next Earnings (Estimated)
3/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:SLNO
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$55.60
High Stock Price Target
$93.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+17.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-24,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.27 per share

Miscellaneous

Free Float
21,716,000
Market Cap
$1.44 billion
Optionable
Optionable
Beta
-1.53
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Anish Bhatnagar M.D. (Age 54)
    President, CEO, COO & Director
    Comp: $835.2k
  • Mr. James H. MacKanessMr. James H. MacKaness (Age 60)
    Chief Financial Officer
    Comp: $539k
  • Ms. Patricia C. Hirano (Age 58)
    Vice President of Regulatory Affairs
    Comp: $423.8k
  • Dr. Neil M. Cowen M.B.A.
    Ph.D., Senior Vice President of Drug Development
  • Ms. Meredith Manning M.B.A. (Age 51)
    Chief Commercial Officer
  • Ms. Kristen Yen M.S. (Age 55)
    Vice President of Clinical Operations
    Comp: $317.19k














SLNO Stock Analysis - Frequently Asked Questions

Should I buy or sell Soleno Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SLNO shares.
View SLNO analyst ratings
or view top-rated stocks.

What is Soleno Therapeutics' stock price target for 2024?

5 brokers have issued 12-month target prices for Soleno Therapeutics' stock. Their SLNO share price targets range from $35.00 to $93.00. On average, they predict the company's stock price to reach $55.60 in the next twelve months. This suggests a possible upside of 17.7% from the stock's current price.
View analysts price targets for SLNO
or view top-rated stocks among Wall Street analysts.

How have SLNO shares performed in 2024?

Soleno Therapeutics' stock was trading at $40.25 at the beginning of the year. Since then, SLNO shares have increased by 17.4% and is now trading at $47.25.
View the best growth stocks for 2024 here
.

When is Soleno Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024.
View our SLNO earnings forecast
.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) released its earnings results on Wednesday, November, 10th. The company reported ($1.50) EPS for the quarter, topping the consensus estimate of ($1.65) by $0.15.

When did Soleno Therapeutics' stock split?

Shares of Soleno Therapeutics reverse split before market open on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vivo Capital LLC (27.60%), Carlyle Group Inc. (9.37%), Nantahala Capital Management LLC (9.37%), Vestal Point Capital LP (4.26%), Vanguard Group Inc. (3.18%) and Balyasny Asset Management L.P. (3.04%). Insiders that own company stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness, Kristen Yen and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLNO) was last updated on 3/5/2024 by MarketBeat.com Staff